MedPath

Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases

Phase 1
Conditions
Colorectal Liver Metastases
Interventions
Radiation: one time radiation
Radiation: No Radiation
Registration Number
NCT01191632
Lead Sponsor
Heidelberg University
Brief Summary

The efficiency of T cell based immunotherapies is affected by the insufficient migration and activity of tumor specific effector T cells in the tumor. Aim of this phase I/II clinical trial is to evaluate whether a neoadjuvant, low dose radiotherapy can improve T cell connected anti tumor immune response in colorectal liver metastases.

The primary endpoint is the number of tumor infiltrating T cells. Furthermore the T cell activity in situ, the number of regulatory T cells and the frequency of tumor reactive T cells in the blood and bone marrow will be examined.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Ability of subject to understand character and individual consequences of the clinical trial
  • Written informed consent (must be available before enrolment in the trial)
  • Age ≥ 50 years
  • Radiological urgently suspected colorectal liver metastasis
Exclusion Criteria
  • second malignancy
  • Pregnancy and lactation
  • no prior liver radiation
  • liver metastasis must be resectable

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Radiation 0,5Gyone time radiationRadiation: one time Radiation with an intensity of 0.5 Gy Group A Beginning on a weekday 48 hours before surgery
No radiationNo RadiationControl group with 0Gy radiation
Radiation 2Gyone time radiationRadiation: one time Radiation with an intensity of 2.0 Gy Group B Beginning on a weekday 48 hours before surgery
Radiation 5Gyone time radiationRadiation: one time Radiation with an intensity of 5 Gy Group C Beginning on a weekday 48 hours before surgery
Primary Outcome Measures
NameTimeMethod
Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity2 years
Secondary Outcome Measures
NameTimeMethod
To determine the progression-free survival in patients treated with low dose photon beam radiation therapy2 years
• To determine the surgical morbidity in patients undergoing liver resection who received this protocol treatment2 years
• To determine 30-day post-operative mortality after liver resection in patients who received this protocol treatment2 years
• To determine the T-cell activity in the resected liver tissue2 years
To determine local control and recurrence patterns of colorectal liver metastases in a CT2 years
• To determine quality of life according to the EORTC QoL questionnaire after 6 months.6 months
To determine the number of regulatory T-cells in the resected liver tissue2 years
To determine the frequencies of tumor-reactive T-cells in the blood and bone marrow of the patients2 years
To determine quality of life according to the EORTC QoL questionnaire after 12 months.1 year
To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria2 years

Trial Locations

Locations (1)

University of Heidelberg

🇩🇪

Heidelberg, Germany

© Copyright 2025. All Rights Reserved by MedPath